Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals

Set Alert for What's Next
What's Next?

What’s Next? Five Things To Look Out For In August

A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In July

This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In June

In June, Medicines for Europe will host its annual and legal affairs conferences in Barcelona, while on the commercial side Hikma’s CEO Siggi Olafsson is to resign from the London-listed company.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In May

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

Generic Drugs Biosimilars
See All

Set Alert for Interviews
Interviews

Hikma Will Push Harder To Make M&A Happen

Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.

Strategy M & A

Cutting Through The Confusion On US Biosimilar Interchangeability

Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk to Generics Bulletin about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings around biosimilars.

Biosimilars Regulation

Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry

Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.

Japan Strategy

Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab

Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.

Biosimilars Market Intelligence
See All

Set Alert for Pricewatch UK
Pricewatch UK

UK Alendronate Prices Explode In July

An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.

Market Intelligence Pricing Strategies

UK Temazepam Prices Shoot Up In June

Temazepam 10mg and 20mg tablets exhibited the steepest UK generic price rises in June, with average prices that nearly quadrupled, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

Risperidone Rises See UK Prices Treble In May

Prices for generic risperidone as much as trebled in the UK in May, leading off increases that also included exemestane and brimonidine tartrate.

Market Intelligence Pricing Strategies

Solifenacin Surges As UK Sees Huge Price Rises In April

Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register